Table 3 Current anlotinib clinical trials for multiple cancers
From: Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Regimen | Study type | Enrollment | Population |
|---|---|---|---|
Anlotinib and irinotecan | Phase III | Recruiting | Advanced Ewing sarcoma |
Anlotinib | Phase II/III | Not recruiting | Advanced soft tissue sarcoma |
Anlotinib | Phase II | Unknown status | Soft tissue sarcoma |
Anlotinib | Phase III | Recruiting | Metastatic or advanced alveolar soft part sarcoma, leiomyosarcoma and synovial sarcoma |
Anlotinib | Phase II | Recruiting | Hepatocellular carcinoma |
Anlotinib | Phase II/III | Recruiting | Medullary thyroid carcinoma |
Anlotinib | Phase II/III | Recruiting | Differentiated thyroid cancer |
Anlotinib | Phase II | Not recruiting | Advanced renal cell carcinoma |
Anlotinib | Phase II | Recruiting | Esophageal squamous cell carcinoma |
Anlotinib plus irinotecan | Phase II | Not recruiting | Esophageal squamous cell carcinoma |
Anlotinib | Phase II | Recruiting | Gastroenteropancreatic neuroendocrine tumor G3 |
Anlotinib | Phase II | Not recruiting | Colorectal cancer |
Anlotinib | Phase II | Recruiting | Small cell lung cancer |
Anlotinib | Phase II/III | Recruiting | Gastric cancer |
Anti-angiogenesis plus EGFR-TKI | Phase II | Not recruiting | Non-squamous non-small cell lung cancer |